실시간
Endpoints NewsCity Therapeutics gets $99M to gather data on three RNAi medicinesClinical OMICsProPure™ Endotoxin-Free Proteins for Reliable Cancer ResearchClinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental ModelsBioPharma DiveRoche stakes $700M on Nurix’s protein-degrading drugClinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care PathwayEndpoints NewsGoHealth files for bankruptcy, as Medicare Advantage insurers pull backAgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.stBioPharma DiveTango data add to growing momentum for pancreatic cancer drugsBioWorldAppointments and advancements for June 8, 2026BioWorldFinancings for June 8, 2026BioWorldIn the clinic for June 8, 2026BioWorldOther news to note for June 8, 2026
FierceBiotech 2026년 4월 24일

Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs

Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.